N.L. Kunelskaya, G.Yu. Tsarapkin, A.Yu. Ivoylov, A.S. Tovmasyan

SBHCI “Scientific Research Clinical Institute of Otorhinolaryngology n.a. L.I. Sverzhevsky” of Moscow Healthcare Department
Over the past 30 years the prevalence of allergic diseases commonly doubled every 10 years. Currently, the problem of allergic rhinitis (AR) can be considered as one of the most pressing. In terms of prevalence, medical and social importance, and impact on health and quality of life of patients, the AR occupies the first place among the other allergic diseases. Over the past few decades a steady increase in the number of patients suffering from this disease has seen in Europe. In the structure of allergic diseases, the proportion of AR is very high (60–70%). According to the results of epidemiological studies, AR affects about 20% of the population in all age groups. The article demonstrates the role of antihistamines in the treatment of AR. Currently, cetirizine, a competitive antagonist of histamine, a metabolite of hydroxyzine, selectively blocking the H1-receptor, is one of the most effective, safe and cost-effective antihistamines with systemic effects. Furthermore, besides antihistamine effect, cetirizine has the additional anti-inflammatory action. Probability of development of tolerance to the drug is low, so it can be used for a long time. Cetirizine is applied once a day that increases adherence to therapy. Cetirizine has well-proven bioequivalence with an original cetirizine, but is more economically available. Cetirizine is one of the most effective and safe second generation antihistamines.

About the Autors

G.Yu. Tsarapkin – MD, SBHCI «Scientific Research Clinical Institute of Otorhinolaryngology n.a. L.I. Sverzhevsky» of Moscow Healthcare Department; tel. 8 (495) 633-92-06

Similar Articles

Бионика Медиа